Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
about
Recent developments in Alzheimer's disease therapeuticsTranslatability scoring in drug development: eight case studiesBiological markers of amyloid beta-related mechanisms in Alzheimer's diseaseThe ubiquitin proteasome system in neuropathologyExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsTargeting γ-secretase in breast cancerNotch signaling as a novel regulator of metabolismHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesPreventing Alzheimer's disease by means of natural selectionBACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemNotch1 represses osteogenic pathways in aortic valve cellsHas inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.Diagnosis and staging of mild cognitive impairment, using a modification of the clinical dementia rating scale: the mCDRBuilding a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.Blood-based biomarkers of Alzheimer's disease: challenging but feasibleTargeting Abeta and tau in Alzheimer's disease, an early interim reportUpdate on the pharmacological treatment of Alzheimer's diseaseA novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer diseaseIntegrating ADNI results into Alzheimer's disease drug development programs.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsGamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrenceEvaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.Commentary on "Design of comprehensive Alzheimer's disease centers to address unmet national needs".Drug development for Alzheimer's disease: where are we now and where are we headed?Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats.Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trialsAmyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Cyclopamine modulates γ-secretase-mediated cleavage of amyloid precursor protein by altering its subcellular trafficking and lysosomal degradationAge-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition.A brief overview of amyloids and Alzheimer's disease.Disease-modifying treatments for Alzheimer's disease.
P2860
Q21245264-014D04F3-43CB-4C57-8BC1-78BBCC7426B0Q22241760-010E7A88-AC05-4AD2-905F-2A215DC10F98Q24622136-4E399FEC-EEB9-49F2-B552-292679AFBC74Q24644208-5D0EA485-EFB3-49CF-90AD-926676B460C4Q26770708-538E92F8-3B83-48AF-9116-DE64941A9AEBQ26784569-02B896B5-2348-4757-A9A8-7BC9BF72F5E8Q27001056-258D683D-A9B5-48E0-AD7A-DD94B560C890Q27014152-F14F73E9-DAAB-4F1A-AADC-701B0AF0954FQ28072061-44D898BE-C5C9-4670-95A4-E7BA56C1ABF0Q28088701-9F45A8AA-8D83-42FB-9645-082A4F5D64E2Q28480522-CC8A26E6-5C16-46C7-BAE3-AA37CF5296A4Q28505877-202C6FA8-060F-4D67-AAE3-F949833E7E48Q30584453-D4D34FD4-639F-4D4E-BEBB-EB8B9FA213C4Q30996799-8CA64283-3A38-417D-804B-6430B914E07BQ33658302-2D1A98E3-F9F1-4031-8A5D-17D426D567F6Q33745617-39985508-B0A8-47B9-A2C7-EFC51B5B1730Q33754484-F1B814F1-B417-41C4-818D-D8DD4E1C3FDDQ33809324-F9554CA8-FE66-4FCC-BC94-6856CB2E5743Q33824444-B5A716A2-E925-4B91-AFF0-63B88A82D845Q33829008-C6915B7B-C628-4B2D-A0EE-D2DDB9B18614Q33836947-A62B0951-B1AE-4277-8BFF-C7C3882B4C6FQ33877903-51762EB6-8B0F-427E-9DC8-F7876DFA06A1Q33987409-2FA09B3C-85FE-4198-AC8D-9DBE45A96C45Q34014237-DF68914C-9A27-4688-8A26-385CADB5EA63Q34101839-5DE291A2-2E49-4CE7-B79B-9C0F49A1D3B2Q34149524-D9D8597F-F6B8-44F1-B038-E1DF64BD76B3Q34166229-42642802-650C-4A33-ACB4-FF700CAEE7FDQ34166256-22E0833B-F241-40F0-B7C1-2DC32F331CA0Q34222721-781A185D-3699-46F7-B9B5-55A81D84CF91Q34315258-2E263BFC-10A5-4561-8809-6E1718984490Q34355472-70D88D67-867B-425F-8D87-D5E481F7852AQ34376103-1F8F75CF-7D56-4FB2-B66B-F68207245F63Q34409349-9ACA4DA5-8D3A-4351-8C43-82BF530E048FQ34441565-2E109A7E-6C4A-456F-8165-AA59213B630FQ34543707-C838EE51-D7FF-4C4F-BBBC-A1FBEF412699Q34543713-F1EBC664-E070-41B1-8AD0-DC563081CB52Q34580289-12117676-F6B2-4475-90A0-E2F140834A63Q34716790-4DEBA9B0-740A-4346-8BF5-C5E513DC3D50Q34868191-BA51BFC8-58FF-47F1-83B7-A4713CEF50FDQ35090423-64980262-677A-4B7B-A084-70C5047ED591
P2860
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase 2 safety trial targeting ...... inhibitor in Alzheimer disease
@en
Phase 2 safety trial targeting ...... nhibitor in Alzheimer disease.
@nl
type
label
Phase 2 safety trial targeting ...... inhibitor in Alzheimer disease
@en
Phase 2 safety trial targeting ...... nhibitor in Alzheimer disease.
@nl
prefLabel
Phase 2 safety trial targeting ...... inhibitor in Alzheimer disease
@en
Phase 2 safety trial targeting ...... nhibitor in Alzheimer disease.
@nl
P2093
P2860
P1433
P1476
Phase 2 safety trial targeting ...... inhibitor in Alzheimer disease
@en
P2093
Abdullah Sherzai
Adam S Fleisher
B Brooke Sowell
Christopher M Clark
Elaine R Peskind
Eric R Siemers
James E Galvin
Joseph F Quinn
Leon J Thal
Lida Becerra
P2860
P304
P356
10.1001/ARCHNEUR.65.8.1031
P577
2008-08-01T00:00:00Z